The PennZone

PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the company's phase 2a clinical trial to study the dose-dependent, safety and efficacy of LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis.

"We are encouraged to be able to provide LP-10 to qualified patients," commented Jonathan Kaufman, Lipella's Chief Executive Officer. "Two clinical sites have started patient screening and recruitment, and we look forward to opening additional sites in the near future."

About Hemorrhagic Cystitis
Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. Certain chemotherapies (such as cyclophosphamide) can also cause this painful form of urinary bleeding. The blood loss, associated with hemorrhagic cystitis can lead to surgery, and can be fatal. There are currently no adequate therapies available for the treatment of moderate to severe hemorrhagic cystitis patients.

More on The PennZone

• Kaltra Expands Microchannel Innovation to Deliver Lower Refrigerant Charge
• Georgia's Lanier Islands Resort Tees Up for a New Era of Golf in Spring 2026
• We Have Lots Of Loads LLC Expands Nationwide
• Eagle Americas Expands Into the Western U.S. With High West Machine Tool
• Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community

About LP-10
LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. Lipella Pharmaceuticals received FDA Orphan Designation for the use of tacrolimus for the treatment of hemorrhagic cystitis.

About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical stage pharmaceutical company with a focus on capital efficient therapeutic development opportunities, including the proprietary repositioning of generics for rare, morbid diseases that currently have no adequate treatments. Additional information is available at http://www.lipella.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause Lipella' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors.

More on The PennZone

• Outsports announces record-breaking number of LGBTQ+ athletes at 2026 Milan Winter Olympics
• Sheffield Clinic Highlights Safe, Inclusive Laser Hair Removal While Improving Access
• Appliance EMT Partners with Kids Motel Ministry in Metro Atlanta
• CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos
• Tech Workers Are Escaping "Forever Layoffs" By Becoming Their Own Boss

Caution: LP-10 is currently not approved for commercial use in any indication in the United States and is limited by U.S. Federal Law to investigational use only.

Key words: hemorrhagic cystitis; radiation cystitis; phase-2a clinical trial; cancer survivorship; 505(b)(2) regulatory pathway; urinary bleeding; painful bladder; liposomal; drug; therapeutic; pharmaceutical

---

Show All News | Report Violation